Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Menstrual disorder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    151 result(s) found for: Menstrual disorder. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2020-006147-25 Sponsor Protocol Number: UTEROXINE Start Date*: 2022-11-15
    Sponsor Name:Centre de Recherche en Santé de la Femme
    Full Title: Botulinum toxin type A injection in patients with chronic pelvic pain of uterine origin (severe dysmenorrhea and/or deep dyspareunia). Phase III, single-center, randomized study vs. control group
    Medical condition: PATIENTS WITH CHRONIC PELVIC PERINEAL PAIN OF UTERINE ORIGIN WITH VAS>4
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10048581 Pelvic pain female LLT
    21.1 10038604 - Reproductive system and breast disorders 10064189 Chronic pelvic pain syndrome LLT
    21.1 10037175 - Psychiatric disorders 10078087 Genito-pelvic pain/penetration disorder PT
    21.1 10038604 - Reproductive system and breast disorders 10011990 Deep dyspareunia LLT
    20.1 10038604 - Reproductive system and breast disorders 10013934 Dysmenorrhea LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002855-48 Sponsor Protocol Number: BAY1002670/15789 Start Date*: 2017-07-12
    Sponsor Name:Bayer AG
    Full Title: A randomized, parallel-group, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids
    Medical condition: Leiomyoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046784 Uterine fibroids LLT
    20.0 100000004864 10016628 Fibroids LLT
    20.0 100000004864 10022794 Intramural leiomyoma of uterus LLT
    Population Age: Adults Gender: Female
    Trial protocol: IE (Completed) SE (Completed) CZ (Completed) HU (Prematurely Ended) FI (Completed) AT (Prematurely Ended) NO (Prematurely Ended) DE (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) DK (Completed) BE (Completed) SK (Completed) LT (Completed) NL (Prematurely Ended) PT (Completed) BG (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000309-60 Sponsor Protocol Number: 120101 Start Date*: 2016-03-30
    Sponsor Name:Göteborgs universitet
    Full Title: Biochemical and neuropsychological effects on Premenstrual Dysphoric Disorder after acute administration of escitalopram
    Medical condition: Premenstrual Dysphoric Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038604 - Reproductive system and breast disorders 10051537 Premenstrual dysphoric disorder PT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001911-31 Sponsor Protocol Number: 30032006 Start Date*: 2007-06-27
    Sponsor Name:Universitätsfrauenklinik Innsbruck
    Full Title: Metformin-Wirkung am Ovar bei PCOS (MAO-Studie) - eine Pilotstudie
    Medical condition: Polycystic ovary syndrome is one of the most common endocrine disorders, affecting approximately 10% of women of reproductive age, associated with hyperandrogenaemia and menstrual dysfunction. The ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014695 Endocrine disorder LLT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001217-25 Sponsor Protocol Number: 2016-001217-25 Start Date*: 2016-09-07
    Sponsor Name:Uppsala University
    Full Title: Emotion, Serotonin and Premenstrual Dysphoric Disorder (EmSeP)
    Medical condition: Premenstrual Dysphoric Disorder
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004081-18 Sponsor Protocol Number: UM104 Start Date*: 2012-12-06
    Sponsor Name:Umecrine Mood AB
    Full Title: A randomized, double-blind, placebo-controlled parallel-group study on safety, tolerability, pharmacokinetics and pharmacodynamics of UC1010 administered subcutaneously, single-dosing in healthy wo...
    Medical condition: Premenstrual Dysphoric Disorder (PMDD)
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002179-91 Sponsor Protocol Number: MLE4901-101 Start Date*: 2017-01-17
    Sponsor Name:Millendo Therapeutics, Inc.
    Full Title: A Double-blind, Randomized, Parallel-group, Placebo-controlled Study of MLE4901 for the Treatment of Polycystic Ovary Syndrome (PCOS)
    Medical condition: Polycystic Ovary Syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000822-37 Sponsor Protocol Number: UM203 Start Date*: 2017-10-30
    Sponsor Name:Asarina Pharma
    Full Title: A phase II, randomised, double-blind, placebo-controlled, parallel-group, multi-centre study investigating efficacy and safety of Sepranolone (UC1010) in patients with PMDD
    Medical condition: Premenstrual dysphoric disorder (PMDD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10051537 Premenstrual dysphoric disorder PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-002217-34 Sponsor Protocol Number: FITO-01/21 Start Date*: 2022-07-26
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI
    Full Title: Tuscany project to investigate on efficacy and safety of Cannabis phytotherapic preparations for the treatment of Aromatase iNhibitor-induced chronic resistaNt pAin in Breast cancer patIents: a pro...
    Medical condition: Aromatase iNhibitor-induced chronic resistaNt pAin in Breast cancer patIents
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003401-87 Sponsor Protocol Number: SND103285 Start Date*: 2006-02-15
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A Ten-Week, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Flexible-Dose Study Evaluating the Efficacy, Safety, and Tolerability of GSK372475 (1.5 mg/day to 2...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) BE (Completed) FR (Completed) EE (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2004-004516-22 Sponsor Protocol Number: 04-4025 Start Date*: 2005-02-01
    Sponsor Name:Uppsala University
    Full Title: The impact of steroid hormones on symptom provocation in patients with premenstrual dysphoric disorder.
    Medical condition: Premenstrual Dysphoric Disorder
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003561-26 Sponsor Protocol Number: BAY1002670/15790 Start Date*: 2017-12-14
    Sponsor Name:Bayer AG
    Full Title: A randomized, parallel-group, double-blind and placebo-controlled, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids
    Medical condition: Leiomyoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10016628 Fibroids LLT
    21.1 100000004864 10046784 Uterine fibroids LLT
    21.1 100000004864 10022794 Intramural leiomyoma of uterus LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-003027-15 Sponsor Protocol Number: EFFI2021/01 Start Date*: 2023-03-20
    Sponsor Name:ITALFARMACO S.P.A.
    Full Title: A multicentre, prospective, open-label, non-comparative study to evaluate menstrual bleeding typology, tolerability, and compliance during a monophasic hormonal contraceptive treatment with norgest...
    Medical condition: Combined Oral Contraceptives (COC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10014698 Endocrine disorders SOC
    Population Age: Adults Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002540-94 Sponsor Protocol Number: UNC4022 Start Date*: 2004-11-25
    Sponsor Name:Norrlands university hospital
    Full Title: Effects of allopregnanolone in women with PMDD, depression, PCOS och oral contraceptives
    Medical condition: PMDD (premenstrual dysphoric disorder) includes depressed mood and anxiety but occurs only during the late phase of the menstrual cycle. Major depression are more common in women and especially pos...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000191-32 Sponsor Protocol Number: 7153L02 Start Date*: 2006-07-28
    Sponsor Name:ZAMBON GROUP
    Full Title: A multicenter, multinational, randomized, parallel group, placebo-controlled, double-blind study to evaluate efficacy and safety of a food supplement containing 80 mg soy isoflavones ZAVITAL in ...
    Medical condition: Menopausal syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.1 10058825 Menopausal disorder LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001719-19 Sponsor Protocol Number: 2016:1 Start Date*: 2016-07-25
    Sponsor Name:Uppsala University
    Full Title: Selecitve progesterone receptor modulators for treatment of premenstrual dysphoric disorder. A randomized, double-blind, placebo controlled study.
    Medical condition: Premenstrual dysphoric disorder
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022647-38 Sponsor Protocol Number: P06107 Start Date*: 2011-11-16
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation
    Full Title: Efficacy and Safety of 3-Week Fixed-Dose Asenapine Treatment in Pediatric Acute Manic or Mixed Episodes Associated with Bipolar I Disorder (Protocol No. P06107)
    Medical condition: Acute Manic or Mixed Episodes Associated with Bipolar I Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10068455 Bipolar I disorder, hypomanic LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-004506-34 Sponsor Protocol Number: 16.022 Start Date*: 2017-01-26
    Sponsor Name:Odense Universitetshospital
    Full Title: The effect of myoinositol (MI) or metformin treatment on symptoms of polycystisk ovary syndrome (PCOS), including metabolism, menstrual pattern, quality of life and mental health.
    Medical condition: Polycystic ovarian syndrome (PCOS)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-022648-19 Sponsor Protocol Number: P05898 Start Date*: 2011-11-16
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation
    Full Title: A 26-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed episodes Associated With Bipolar I Disorder
    Medical condition: Acute Manic or Mixed Episodes Associated with Bipolar I Disorder
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10068455 Bipolar I disorder, hypomanic LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002658-11 Sponsor Protocol Number: 12712B Start Date*: 2016-06-08
    Sponsor Name:H. Lundbeck A/S
    Full Title: Long-term, open-label, flexible-dose, continuation extension study with vortioxetine in child and adolescent patients with Major Depressive Disorder (MDD) from 7 to 17 years of age
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) LV (Completed) HU (Completed) EE (Completed) ES (Completed) IT (Completed) DE (Completed) BG (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 07:32:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA